IVD News and Research

RSS

Re-defining the limits of single batch assay stabilisation

In response to increasing demand for stabilised molecular diagnostic assays, we have significantly increased our single batch lyophilised reagent bead manufacturing throughput to 300,000 reactions per freeze drying run and are now progressing towards a capacity of 100 million tests per annum.

From Biofortuna Limited 22 Aug 2022

Rapidly growing nanotechnology firm launches new identity as MIP Discovery

MIP Diagnostics, a leading UK nanotechnology firm has today rebranded to MIP Discovery as the business continues its expansion within the healthcare sector.

From MIP Discovery 19 May 2022

The Nucleic Acid Experts – Certified Twice!

BioEcho Life Sciences receives two important hallmarks for its quality management – DIN EN ISO 9001:2015 and DIN EN ISO 13485:2016.

From BioEcho Life Sciences GmbH 10 Mar 2022

MIP Diagnostics secures £7.3M investment following achievement of critical milestones

Mercia Asset Management, Calculus Capital, Downing Ventures and BGF scale joint investment in latest fundraise.

From MIP Discovery 1 Mar 2022

Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer

Joint study will assess clinical value of comprehensive genomic profiling (CGP) on cancer therapy options in patients with advanced disease

17 Feb 2022

Expanded range of nucleic acid extraction kits for pathogens detection

AMSBIO announce the addition of several new products to its growing range of magnetic bead based nucleic acid extraction kits for pathogens detection.

From AMS Biotechnology 9 Feb 2022

Synthetic antibody demonstrates Omicron detection along with all other variants of concern

MIP Diagnostics Ltd. has today announced that its synthetic SARS-CoV-2 antibody (COVID-19 nanoMIPTM) can detect the Omicron variant as well as previously proven Alpha, Beta, Delta and Gamma variants of the COVID-19 virus.

14 Jan 2022

MIP Diagnostics to support the development of challenging affinity reagents with new Molecular Imprinting Epitope Discovery

MIP Diagnostics has today announced the launch of its novel Molecular Imprinting Epitope Discovery Service.

26 Oct 2021

New research sheds light on the working principles of advanced biosensing technologies

The COVID-19 pandemic is undoubtedly the most challenging global health burden since the 2nd World War. The pandemic has raised social awareness on the importance of effective and timely diagnosis that may help minimize the risk of contracting and spreading COVID-19.

22 Oct 2020